online

Michel Burnier on Drug Adherence and Compliance

Michel Burnier (Switzerland) answers the following questions:

- Please explain the difference between drug adherence and drug compliance.

- What is the role of adherence in resistant or difficult to control hypertension? (30-40% of patients are not adherent)

- How do you control drug compliance in daily clinical practice in your patients?

- Where do you see the role of the GP in the adherence system of a patient?

Exclusive interview

Thomas F. Lüscher answers the following questions: - Can you please tell us more about the design of the SYMPLICITY HTN-3 trial?...

Thomas Zeller on Renal Artery Stenosis

Thomas Zeller (Germany) answers the following questions:

- Do you screen every hypertensive patient for renal artery stenosis?

- Which is the best imaging method to detect renal artery stenosis and why?

- Can you please provide us with a short summary of the CORAL trial?

- Do you still believe in the role of renal artery stenting?

- How does the press release of SYMPLICITY HTN-3 influence your daily practice?

Thomas F. Lüscher - About the Symplicity HTN-3 trial

Thomas F. Lüscher (Switzerland) answers the following questions:

- Can you please tell us more about the design of the SYMPLICITY HTN-3 trial?

- What are your thoughts on the Medtronic press release and how does it affect your daily practice?

- Please can you share your opinion about future indications for renal denervation for the future?

Watch the interview of M. Böhm

Michael Böhm answers the following questions: - How does the Symplicity HTN-3 update affect your work? Do you continue renal denervation?...

Michael Böhm - About the Symplicity HTN-3 press release

Michael Böhm (Germany) answers the following questions:

- How does the Symplicity HTN-3 update affect your work? Do you continue renal denervation?

- Further indications for renal denervation?

- Can you please summarise the main points of the ReAdapt CHF trial?

Pages